Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PELUR: Neoadjuvant Pembrolizumab + Lenvatinib in Advanced RCC
NCT05485896Phase 2Completed
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Jul 2022
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, lenvatinib in renal cell carcinoma (RCC), sponsored by The Second Hospital of Tianjin Medical University. Started Jul 2022; status: completed.
02
Drugs
pembrolizumablenvatinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05485896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05485896.